Claims:

1. A red blood cell extracellular vesicle (RBCEV) comprising an exogenous polypeptide tag, wherein the tag comprises a protein ligase recognition sequence and is covalently linked to a native membrane protein of the extracellular vesicle.

2. The RBCEV according to claim 1, wherein the tag further comprises one or more functional domain(s) wherein the functional domain is capable of binding to a target moiety, capable of being detected and/or capable of inducing a therapeutic effect.

3. The RBCEV according to claim 2, wherein the functional domain comprises an antibody or antigen binding fragment, preferably a sdAb.

4. The RBCEV according to any one of the preceding claims, wherein the tag further comprises a protein ligase binding site.

54. The RBCEV according to any one of the preceding claims, wherein the extracellular vesicle is a microvesicle or exosome, preferably a microvesicle.

65. The RBCEV according to any one of the preceding claims, wherein the extracellular vesicle is loaded with a cargo.

76. The RBCEV according to claim 65, wherein the cargo is a nucleic acid, peptide, protein or small molecule.

87. The RBCEV according to claim 76, wherein the cargo is a nucleic acid selected from the group consisting of an antisense oligonucleotide, a messenger RNA, a long RNA, a siRNA, a miRNA, a gRNA or a plasmid.

98. A composition comprising one or more RBCEVs according to any one of claims 1 – 87.

10~~9~~. An RBCEV or composition according to any one of ~~the preceding~~ claims 2-9, for use in a method of treatment.

~~10. A method of treatment, the method comprising administering an RBCEV according to claim 1 to a patient in need of treatment.~~

11. Use of an RBCEV or composition according to any one of claims 2~~1~~-9~~10~~ in the manufacture of a medicament for the treatment of a disease or disorder~~.~~, wherein the disease or disorder is a genetic disorder, inflammatory disease, cancer, autoimmune disorder, cardiovascular disease or a gastrointestinal disease.

12. The RBCEV or composition for use according to claim 10, ~~method of treatment or use according to any one of claims 9-11~~ wherein the ~~method of treatment involves administration of an~~ RBCEV or composition according to any one of claims 2~~1~~-9~~8~~ is to be administered to a subject with a genetic disorder, inflammatory disease, cancer, autoimmune disorder, cardiovascular disease or a gastrointestinal disease.

13. The RBCEV or composition for use according to claim 12, ~~method of treatment~~ or the use according to claim 11~~12~~, wherein ~~the subject has cancer,~~ the cancer is optionally selected from leukemia, lymphoma, myeloma, breast cancer, lung cancer, liver cancer, colorectal cancer, nasopharyngeal cancer, kidney cancer or glioma.

14. A method comprising contacting an RBCEV with a tag and a protein ligase under conditions which allow covalent binding between the tag and a native surface protein of the extracellular vesicle, thereby generating a tagged RBCEV.

15. A method comprising:

(a) contacting an RBCEV with a peptide and first protein ligase under conditions which allow covalent binding between the peptide and a native surface protein of the extracellular vesicle, thereby generating a peptide tagged RBCEV; and

(b) contacting the peptide tagged RBCEV with a functional domain peptide and a second protein ligase under conditions which allow covalent binding between the peptide covalently bound to the RBCEV and the functional domain peptide.

16. The method according to claim 15 wherein the first and second ~~peptide~~protein ligases are the same.

17. The method according to claim 15 wherein the first and second protein~~peptide~~ ligases are different.

18. The method of claim 14 or claim 15 wherein the method further comprises contacting the RBCEV with a cargo and electroporating to encapsulate the cargo with the RBCEV.

19. The method according to any one of claims 15 to 17 wherein the protein ligase is selected from the group consisting of a sortase or AEP1, preferably sortase A.

20. An RBCEV obtained by a method according to any one of claims 14-19.